DOI: 10.1055/s-00034914

Osteologie

References

Langdahl BL, Libanati C, Crittenden DB. et al.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Lancet 2017;
390 (10102): 1585-1594

Download Bibliographical Data

Access:
Access: